The company intends to use the funds to expand its commercial footprint and advance its clinical and development activities related to Aliya® PEF in solid tumors and RheOx® therapy for chronic bronchitis, and to continue to innovate its novel PEF platform, a non-pharmacologic intervention which uses non-thermal, short-duration, highly focused electrical pulses that destabilize cellular pathologic processes in hopes of changing the disease trajectory for these patients.

Company Information

Company Status

Private & Independent

Industry

Medical Devices & Instruments

Mailing Address

3200 Bridge Parkway
Redwood City, CA 94065
USA

Phone

(650) 268-4252

Website

www.galvanizetx.com

Email Address

[email protected]

Overview

Galvanize is a biomedical platform company operating at the convergence of engineering, biology, and healthcare delivery, aiming to deliver life-changing solutions to patients and their doctors.

Profile

Social Media

Galvanize Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Jonathan Waldstreicher

Browse more venture capital transactions:

Prev: 9/3/2025: Exa venture capital transaction
Next: 9/3/2025: HappyRobot venture capital transaction

Share this article

Where The Data Comes From

We report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary